Transmucosal Delivery of Linagliptin for the Treatment of Type-2 Diabetes Mellitus by Ultra-Thin Nanofibers

被引:13
|
作者
Modgill, Vedant [1 ]
Garg, Tarun [1 ]
Goyal, Amit K. [1 ]
Rath, Goutam [1 ]
机构
[1] ISF Coll Pharm, Dept Pharmaceut, Moga 142001, Punjab, India
关键词
Anti-diabetic; nanofibers; polyvinyl alcohol; linagliptin; controlled release; BIOACTIVE DRUG MOLECULES; SCAFFOLDS; SYSTEMS; HYDROGEL;
D O I
10.2174/1567201811666141117144332
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of the present research was to cultivate an oral formulation of an anti-diabetic drug using polymeric nanofiber. A biodegradable polymer i.e. poly (vinyl alcohol) (PVA) nanofiber loaded linagliptin was prepared using electro spinning technique. The drug entrapment in the developed nanofibers was confirmed by scanning electron microscopy and X-ray diffraction. The in vivo study was performed on male Wistar rats to establish the pharmacodynamics behavior of developed formulation. The mucoadhesive strength results confirmed that the drug loaded PVA nanofiber patch had the highest mucoadhesion strength compare to PVA film and blank PVA nanofiber, due to its higher water holding capacity and surface area. The in vitro release study suggested that controlled release array of the drug from the nanofiber patch. In vivo activity validated the fact that linagliptin was delivered in its active state and showed visible results when compared to the commercial formulation. Additionally an encapsulation efficacy of 92% of the experimental formulation provides sufficient suggestion that the nanofibers serve as an ideal carrier for the delivery of linagliptin via the sublingual route.
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [41] Linagliptin versus glimepiride add-on for the long-term treatment of Type 2 diabetes mellitus
    Chilton, Robert
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (04) : 345 - 349
  • [42] Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus
    Yu. S. Gavrilova
    N. P. Bgatova
    V. V. Klimontov
    I. Yu. Ischenko
    S. V. Michurina
    N. E. Myakina
    E. L. Zavyalov
    Bulletin of Experimental Biology and Medicine, 2016, 161 : 501 - 504
  • [43] PANCREATIC ABNORMALITIES IN TYPE-2 DIABETES-MELLITUS
    CONNOLLY, AAP
    LANCET, 1988, 1 (8581): : 359 - 359
  • [44] Prevalence of comorbidities in patients with type-2 diabetes mellitus
    Akin, Seydahmet
    Boluk, Cem
    PRIMARY CARE DIABETES, 2020, 14 (05) : 431 - 434
  • [45] Metabolic syndrome in subjects with type-2 diabetes mellitus
    Alebiosu, CO
    Odusan, BA
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2004, 96 (06) : 817 - 821
  • [46] Liver Function in Type-2 Diabetes Mellitus Patients
    Mathur, Shipra
    Mehta, Debij Kumar
    Kapoor, Sangeeta
    Yadav, Sushil
    INTERNATIONAL JOURNAL OF SCIENTIFIC STUDY, 2016, 3 (10) : 43 - 47
  • [47] Erratum to: Linagliptin: a review of its use in the management of type 2 diabetes mellitus
    Emma D. Deeks
    Drugs, 2013, 73 : 99 - 99
  • [48] GENOMIC DAMAGE IN PATIENTS WITH TYPE-2 DIABETES MELLITUS
    Binici, D. N.
    Karaman, A.
    Coskun, M.
    Ogiu, A. Uyanik
    Ucar, F.
    GENETIC COUNSELING, 2013, 24 (02): : 149 - 156
  • [49] Serum Magnesium and Dyslipidemia in Type-2 Diabetes Mellitus
    Mishra, Sasmita
    Padmanaban, P.
    Deepti, G. N.
    Sarkar, G.
    Sumathi, S.
    Toora, B. D.
    BIOMEDICAL RESEARCH-INDIA, 2012, 23 (02): : 295 - 300
  • [50] INCIDENCE OF NEPHROPATHY IN TYPE-2 DIABETES-MELLITUS
    KUNZELMAN, C
    PETTITT, D
    BENNETT, P
    KNOWLER, W
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1985, 122 (03) : 547 - 548